www.domainex.co.uk Open in urlscan Pro
77.68.94.219  Public Scan

Form analysis
1 forms found in the DOM

GET /search/node

<form action="/search/node" method="get" id="search-block-form" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-keys js-form-item-keys form-no-label">
    <label for="edit-keys" class="visually-hidden">Search</label>
    <input title="Enter the terms you wish to search for." data-drupal-selector="edit-keys" type="search" id="edit-keys" name="keys" value="" size="15" maxlength="128" class="form-search">
  </div>
  <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions"><input data-drupal-selector="edit-submit" type="submit" id="edit-submit" value="Search" class="button js-form-submit form-submit">
  </div>
</form>

Text Content

YOUR CHOICE REGARDING COOKIES ON THIS SITE

We use cookies to optimise site functionality and give you the best possible
experience.

I Accept CookiesI Do Not Accept CookiesSettings
Skip to main content

 * About
   * About
   * Case Studies
   * Testimonials
   * Awards
   * Board members
   * Investors
   * Management team
   * Contact us
 * Services
   * Offerings
     * Integrated Drug Discovery Services
     * Protein Expression and Purification Services
     * X-ray crystallography
     * Assay Development
     * Biophysical Assays
     * Biochemical Assays
     * Synthetic Chemistry
     * Virtual screening
     * Fragment and Compound Screening
     * Computational Chemistry
     * Medicinal Chemistry
     * Cell Based Assays
     * ADME and Bioanalytical Sciences
     * Analytical Chemistry
   * Research Phases
     * Hit Identification
     * Hit to Lead
     * Lead Optimisation
   * Therapeutic Areas
     * Oncology
     * Immuno-Oncology
     * Cardiovascular
     * Respiratory
     * Anti-infectives
     * Inflammatory diseases
     * CNS Drug Discovery
   * Target Classes
     * Kinases
     * GPCRs
     * Proteases
     * Methyltransferases
     * Ion Channels
     * Protein-Protein Interactions
   * Approaches & Techniques
     * CDH (Target Gene Fragmentation)
     * PoLiPa (Membrane Protein Solubilisation)
     * LeadBuilder
     * FragmentBuilder
     * Fragment Based Drug Discovery (FBDD)
     * Structure Based Drug Design (SBDD)
     * Differential Scanning Fluorimetry (DSF) and nanoDSF Services
     * Grating-Coupled Interferometry
     * High Throughput Screening
     * MicroScale Thermophoresis (MST) Services
     * Targeted Protein Degradation
 * Library
   * Articles
   * Brochures
   * Newsletters
   * Posters
   * Presentations & Videos
   * Publications
   * White Papers
 * News & Events
 * Careers

Search

 * English
 * French
 * Spanish
 * German
 * Italian
 * Japanese
 * Dutch

Enquire


ENRICH YOUR MEDICINES PIPELINE


THE RESEARCH PARTNER THAT CREATES INNOVATIVE SOLUTIONS, BUILDS DYNAMIC
RELATIONSHIPS AND ENRICHES YOUR MEDICINES PIPELINE ACROSS A RANGE OF HUMAN
DISEASES

Our Services


OUR VISION AND MISSION

Our strong vision and mission statements underpin everything we do at Domainex.
They guide our team with a common purpose that ensures we deliver outstanding
drug discovery services to our clients.

Find out more


INTEGRATED DRUG DISCOVERY SERVICES

We offer a truly integrated approach for a faster route to drug discovery. Our
dedicated experts will work collaboratively with you to provide tailored
scientific solutions.

Find out more

 




OFFERINGS

 * Fragment and Compound Screening
 * Cell Based Assays
 * Medicinal Chemistry
 * Synthetic Chemistry
 * Computational Chemistry
 * Analytical Chemistry
 * Protein Expression and Purification Services
 * ADME and Bioanalytical Sciences
 * X-Ray crystallography
 * Biochemical Assays
 * Biophysical Assays
 * Assay Development


RESEARCH PHASES

 * Lead Optimisation
 * Hit to Lead
 * Hit Identification


THERAPEUTIC AREAS

 * Inflammatory diseases
 * CNS Drug Discovery
 * Oncology
 * Immuno-Oncology
 * Cardiovascular
 * Respiratory Disease
 * Anti-infectives


TARGET CLASSES

 * Protein-Protein Interactions
 * Kinases
 * GPCRs
 * Proteases
 * Protein Methyltransferases
 * Ion Channels


APPROACHES & TECHNIQUES

 * Ligand binding assays by Surface Plasmon Resonance (SPR) and/or
   Grating-Coupled Interferometry (GCI)
 * MicroScale Thermophoresis (MST) Services
 * Differential Scanning Fluorimetry (DSF) and nanoDSF Services
 * High Throughput Screening
 * Targeted Protein Degradation
 * CDH (Target Gene Fragmentation)
 * LeadBuilder – Virtual Screening
 * FragmentBuilder: Fragment-Based Drug Discovery and Design
 * Innovative Polymer Lipid Particle (PoLiPa) Technology
 * Structure Based Drug Design (SBDD)


CASE STUDIES

Previous

MAP4K4: KINASE INHIBITORS FOR CARDIOPROTECTION FOLLOWING HEART ATTACKS

Domainex designed novel, potent, highly selective, small-molecule inhibitors of
MAP4K4, with potential cardioprotective drug properties. View more

TANKYRASE: INHIBITORS FOR THE TREATMENT OF SOLID TUMOURS

Domainex employed its LeadBuilder virtual screening technology to identify
tankyrase inhibitors from which pre-clinical development candidates emerged.
View more

DER P 1: PROTEASE INHIBITORS FOR THE TREATMENT OF ASTHMA

Domainex collaborated with St George’s University London & the University of
Manchester on a programme of drug discovery which led to the successfully
nomination of a candidate drug. View more

TBK1/IKKΕ: KINASE INHIBITORS FOR THE TREATMENT OF INTERFERONOPATHIES

Domainex identified a drug candidate DMXD-011, a first-in-class small-molecule
orally bioavailable inhibitor of TBK1/IKKε View more

FLIPP-FADD: PPI INHIBITORS FOR THE TREATMENT OF SOLID TUMOURS

Domainex and Queen's University Belfast have discovered the world’s first
inhibitors of FLIP-FADD and produced viable leads for drug candidate selection
View more

RAS: PPI INHIBITORS FOR THE TREATMENT OF CANCER

Domainex used its extensive experience of fragment- & structure-based drug
design to develop a lead molecule with strong binding to RAS, an oncology
target. View more

G9A: LYSINE METHYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER

Starting from a LeadBuilder screen we identified novel potent inhibitors of G9a,
which have potential to be developed as treatments for a range of solid tumours.
View more

G9A: A FRAGMENT-BASED DRUG DESIGN (FBDD) PROGRAMME TO IDENTIFY LYSINE
METHYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER

Domainex identified several highly efficient fragment hits and after one round
of elaboration a 10-fold increase in affinity was achieved. View more
Next
 * 1
 * 2
 * 3


NEWS

SYNTHESIS IN REVIEW: LIGHT ENABLES OZONE-TYPE REACTIVITY OF NITROARENES AND
HYDROGEN ATOM TRANSFER OF ALKANES

20 Oct '22
Blog Post

AMPHISTA THERAPEUTICS PARTNERS WITH DOMAINEX TO ADVANCE PORTFOLIO OF DRUG
DISCOVERY PROJECTS TARGETING PROTEIN DEGRADATION

6 Oct '22
Press Release

ANTI-INFLAMMATORY DRUG CANDIDATE DMXD-011 SHOWS EFFICACY IN EX-VIVO HUMAN
STUDIES

14 Sep '22
Press Release

MEET THE DOMAINEX TEAM: CAMERON HADDOW

11 Aug '22
Blog Post

SYNTHESIS IN REVIEW: NEW SYNTHETIC METHODS TO ACCESS STEREOGENIC-AT-P(V)
COMPOUNDS AND TRIFLUOROMETHYLATED ANALOGUES

10 Aug '22
Blog Post

MEDICINAL CHEMISTRY IN REVIEW: METABOLIC HYDROLYSIS OF HETEROARYL/ARYL
SULFONAMIDES; A POTENTIAL TOXICOLOGICAL FLAG

8 Aug '22
Blog Post
View more


EVENTS

DEC 7 GENESIS

DEC 9 POSTGRADUATE SYMPOSIUM XVI – BIOLOGICAL AND MEDICINAL CHEMISTRY SYMPOSIUM
FOR POSTGRADUATES 2022

View more


TWEETS



Start your next project with Domainex

Contact one of our experts today
 * About
   * About
   * Case Studies
   * Testimonials
   * Awards
   * Board members
   * Investors
   * Management team
   * Contact us
 * Services
   * Offerings
     * Integrated Drug Discovery Services
     * Protein Expression and Purification Services
     * X-ray crystallography
     * Assay Development
     * Biophysical Assays
     * Biochemical Assays
     * Synthetic Chemistry
     * Virtual screening
     * Fragment and Compound Screening
     * Computational Chemistry
     * Medicinal Chemistry
     * Cell Based Assays
     * ADME and Bioanalytical Sciences
     * Analytical Chemistry
   * Research Phases
     * Hit Identification
     * Hit to Lead
     * Lead Optimisation
   * Therapeutic Areas
     * Oncology
     * Immuno-Oncology
     * Cardiovascular
     * Respiratory
     * Anti-infectives
     * Inflammatory diseases
     * CNS Drug Discovery
   * Target Classes
     * Kinases
     * GPCRs
     * Proteases
     * Methyltransferases
     * Ion Channels
     * Protein-Protein Interactions
   * Approaches & Techniques
     * CDH (Target Gene Fragmentation)
     * PoLiPa (Membrane Protein Solubilisation)
     * LeadBuilder
     * FragmentBuilder
     * Fragment Based Drug Discovery (FBDD)
     * Structure Based Drug Design (SBDD)
     * Differential Scanning Fluorimetry (DSF) and nanoDSF Services
     * Grating-Coupled Interferometry
     * High Throughput Screening
     * MicroScale Thermophoresis (MST) Services
     * Targeted Protein Degradation
 * Library
   * Articles
   * Brochures
   * Newsletters
   * Posters
   * Presentations & Videos
   * Publications
   * White Papers
 * News & Events
 * Careers

COVID-19

+44 (0) 1223 743170 enquiries@domainex.co.uk


OFFERINGS

 * Fragment and Compound Screening
 * Cell Based Assays
 * Medicinal Chemistry
 * Synthetic Chemistry
 * Computational Chemistry
 * Analytical Chemistry
 * Protein Expression and Purification Services
 * ADME and Bioanalytical Sciences
 * X-Ray crystallography
 * Biochemical Assays
 * Biophysical Assays
 * Assay Development


RESEARCH PHASES

 * Lead Optimisation
 * Hit to Lead
 * Hit Identification


THERAPEUTIC AREAS

 * Inflammatory diseases
 * CNS Drug Discovery
 * Oncology
 * Immuno-Oncology
 * Cardiovascular
 * Respiratory Disease
 * Anti-infectives


TARGET CLASSES

 * Protein-Protein Interactions
 * Kinases
 * GPCRs
 * Proteases
 * Protein Methyltransferases
 * Ion Channels


APPROACHES & TECHNIQUES

 * Ligand binding assays by Surface Plasmon Resonance (SPR) and/or
   Grating-Coupled Interferometry (GCI)
 * MicroScale Thermophoresis (MST) Services
 * Differential Scanning Fluorimetry (DSF) and nanoDSF Services
 * High Throughput Screening
 * Targeted Protein Degradation
 * CDH (Target Gene Fragmentation)
 * LeadBuilder – Virtual Screening
 * FragmentBuilder: Fragment-Based Drug Discovery and Design
 * Innovative Polymer Lipid Particle (PoLiPa) Technology
 * Structure Based Drug Design (SBDD)

Domainex is a registered company (number 4336899)

Site and its contents Copyright © Domainex 2022. All rights reserved.

Terms and Conditions | Privacy Policy